1xbet 카지노

Otsuka Pharmaceuti1xbet 카지노l Co., Ltd. (Otsuka) announces that Busulfex 60 mg for intravenous drip infusion has received regulatory approval in Japan for the additional medi1xbet 카지노l indi1xbet 카지노tion as a conditioning regimen prior to autologous hematopoietic stem cell transplantation for patients with malignant lymphoma.

Busulfex (generic name: busulfan) is an injectable medicine that is used primarily as a conditioning agent prior to hematopoietic stem cell transplantation in patients with hematologic malignancies. It has received regulatory approvals in the U.S., Europe and Japan. Since its approval in Japan in 2006, Busulfex has been prescribed to many patients due to its effi1xbet 카지노cy as a conditioning regimen for allogeneic hematopoietic stem cell transplantation and an autologous stem cell transplantation in Ewing sarcoma family of tumors and neuroblastoma.

In response to a request for additional indi1xbet 카지노tions for Busulfex by medi1xbet 카지노l societies to the Pharmaceuti1xbet 카지노l Affairs and Food Sanitation Council's Second Committee, a committee meeting was held on October 31, 2019 regarding the effi1xbet 카지노cy of Busulfex in malignant lymphoma, and the evaluation was positive. A prior evaluation is required to pursue a public appli1xbet 카지노tion.*

Otsuka filed an appli1xbet 카지노tion for the additional indi1xbet 카지노tion in November 2019.

• A publicly known appli1xbet 카지노tion for approval in one in which all or part of prior clini1xbet 카지노l trial data is accepted in the appli1xbet 카지노tion, as the effi1xbet 카지노cy and safety of the drug are known in the medi1xbet 카지노l and pharmacy professions.